Letolizumab

Letolizumab is a monoclonal antibody designed for the treatment of autoimmune diseases. It is currently under development by Biocon Biologics and Viatris.

History

Letolizumab was originally developed by Biocon Biologics, a subsidiary of Biocon, an Indian biopharmaceutical company. In 2020, Biocon Biologics partnered with Viatris, a global healthcare company, to further develop and commercialize the drug.

Mechanism of Action

Letolizumab is a monoclonal antibody that targets the CD6 protein, a surface molecule present on T cells. By binding to CD6, letolizumab inhibits the activation and proliferation of T cells, thereby reducing the immune response that contributes to autoimmune diseases.

Clinical Trials

Letolizumab has undergone several clinical trials to evaluate its safety and efficacy in treating autoimmune diseases. These trials have shown promising results, with letolizumab demonstrating a good safety profile and potential efficacy in reducing symptoms of autoimmune diseases.

Potential Uses

Letolizumab is being investigated for use in a variety of autoimmune diseases, including rheumatoid arthritis, psoriasis, and multiple sclerosis. Further clinical trials are needed to confirm its efficacy and safety in these conditions.

See Also

• Monoclonal antibodies
• Autoimmune diseases
• Clinical trials
• Biocon
• Viatris

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

   This article is a medical stub. You can help WikiMD by expanding it!